<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04944953</url>
  </required_header>
  <id_info>
    <org_study_id>HG-BOT102GL-PI-01</org_study_id>
    <nct_id>NCT04944953</nct_id>
  </id_info>
  <brief_title>To Compare the Safety and Efficacy of &quot;HG-102&quot; With Botox® in the Improvement of Moderate to Severe Glabellar Lines.</brief_title>
  <official_title>Double-blinded, Randomized, Active Control, Single Center-designed, Phase I Clinical Trial to Evaluate the Safety and Efficacy for Improvement of Glabellar Lines of &quot;HG-102&quot; Compared to Botox® in Subjects With Moderate to Severe Glabellar Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hugel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hugel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety and efficacy of &quot;HG-102&quot; with Botox® in the improvement of moderate to&#xD;
      severe glabellar lines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blinded, Randomized, Active control, Single center-designed, Phase I clinical trial to&#xD;
      evaluate the safety and efficacy for improvement of Glabellar Lines of &quot;HG-102&quot; compared to&#xD;
      Botox® in subjects with moderate to severe Glabellar Lines&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 11, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Actual">September 2, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event and adverse drug reaction incidence rates</measure>
    <time_frame>Baseline to week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically-relevant changes in vital signs, physical exam, and laboratory testing assessed by medical personnel</measure>
    <time_frame>16 weeks (during the clinical trial)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responder rate of improvement in glabellar lines with Physician's rating line severity</measure>
    <time_frame>Baseline to week 4, 8, 12, 16</time_frame>
    <description>Improvement rate of glabellar lines at maximum frown with Physician's rating line severity at 4, 8, 12, 16 weeks post injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate of improvement in glabellar lines with investigator's photo assessment</measure>
    <time_frame>Baseline to week 4, 8, 12, 16</time_frame>
    <description>Improvement rate of glabellar lines at maximum frown with investigator's photo assessment at 4, 8, 12, 16 weeks post injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate of improvement in glabellar lines with Physician's rating line severity</measure>
    <time_frame>Baseline to week 4, 8, 12, 16</time_frame>
    <description>Improvement rate of glabellar lines at rest with Physician's rating line severity at 4, 8, 12, 16 weeks post injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate of improvement in glabellar lines with investigator's photo assessment</measure>
    <time_frame>Baseline to week 4, 8, 12, 16</time_frame>
    <description>Improvement rate of glabellar lines at rest with investigator's photo assessment at 4, 8, 12, 16 weeks post injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in grade by physician's rating line severity for glabellar lines</measure>
    <time_frame>Baseline to week 4, 8, 12, 16</time_frame>
    <description>Changes in grade(range from 0(None) to 3(Severe)) by physician's rating line severity for glabellar lines at each visit compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate of improvement in glabellar lines with Subject's improvement assessment</measure>
    <time_frame>Baseline to week 4, 8, 12, 16</time_frame>
    <description>Improvement rate of glabellar lines with Subject's improvement assessment at 4, 8, 12, 16 weeks post injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's satisfaction rate</measure>
    <time_frame>Baseline to week 4, 8, 12, 16</time_frame>
    <description>Subject's satisfaction rate of improvement in glabellar lines at 4, 8, 12, 16 weeks post injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The severity of pain evaluated by the subject's Simple Descriptive Scale (SDS)</measure>
    <time_frame>Baseline</time_frame>
    <description>The severity of pain evaluated by the subject's Simple Descriptive Scale (SDS) at immediately and about 30 minutes post injection (severity range is from 1(no pain) to 5(unbearable pain))</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Glabellar Lines</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin type A(Botox®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Botulinum toxin type A(Botox®) 100 Unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum toxin type A(HG-102)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum toxin type A(HG-102) 100 Unit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A Injection [Botox]</intervention_name>
    <description>Single administration, Day 0, 20 units</description>
    <arm_group_label>Botulinum toxin type A(Botox®)</arm_group_label>
    <other_name>Botox®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A injection [HG-102]</intervention_name>
    <description>Single administration, Day 0, 20 units</description>
    <arm_group_label>Botulinum toxin type A(HG-102)</arm_group_label>
    <other_name>HG-102</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged between 19 and 65 at screening visit.&#xD;
&#xD;
          -  Patients who voluntarily sign the informed consent.&#xD;
&#xD;
          -  Patients who can comply with the study procedures and visit schedule.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with infection, skin disorders, or scars at the glabellar region.&#xD;
&#xD;
          -  Patients with facial palsy or the symptoms of blepharoptosis.&#xD;
&#xD;
          -  Fertile women and men who have plans to conceive during pregnancy, breastfeeding and&#xD;
             clinical trials or who do not agree to appropriate contraception.&#xD;
&#xD;
          -  Subjects who are not eligible for this study based on investigator's judgement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

